Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.33 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.33 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17078047 | 0.84 | HDAC8 (0.37) | APPHDAC8PTGS2GRM5 | |
| SCHEMBL25401176 | 0.79 | APP (0.40) | APPCYP11B1CYP11B2DAOCYP3A4 | |
| SCHEMBL30591958 | 0.79 | APP (0.40) | APPCYP11B1CYP11B2DAOCYP3A4 | |
| SCHEMBL18254190 | 0.79 | HDAC8 (0.39) | HDAC8PTGS2GRM5 | |
| SCHEMBL434088 | 0.79 | APP (0.40) | APPCYP11B1CYP11B2DAOCYP3A4 | |
| SCHEMBL3749196 | 0.77 | CYP11B1 (0.43) | CYP11B1CYP11B2DAOCYP3A4CYP2C9 | |
| SCHEMBL6551393 | 0.77 | HDAC8 (0.46) | HDAC8PTGS2GRM5 | |
| SCHEMBL347778 | 0.75 | CES2 (0.41) | — | |
| SCHEMBL21133837 | 0.72 | HDAC8 (0.34) | HDAC8PTGS2GRM5 | |
| SCHEMBL28825569 | 0.72 | NFE2L2 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181240-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9096591-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150182509-A1 | TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES, INC. | 2015-07-02 | — | — | US | disclosed |
| US-9034880-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-8999978-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20140194414-A1 | TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20130203746-A1 | TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES INC. | 2013-08-08 | — | — | US | disclosed |
| US-20130190304-A1 | TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130131054-A1 | TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-8338408-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| CN-101952284-A | Novel tetracyclic compounds | MEDIVATION TECHNOLOGIES INC | 2011-01-19 | — | — | CN | disclosed |
| EP-2217598-A1 | NEW TETRACYCLIC COMPOUNDS | Medivation Technologies, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| US-20090239854-A1 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. | 2009-09-24 | — | — | US | disclosed |
| WO-2009055828-A1 | NEW TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150182509-A1 | TETRACYCLIC COMPOUNDS | HTR2C, HTR3D, HTR5A | APP 582/4885HDAC8 3361/4885CYP11B1 4436/4885 |
| US-20130131054-A1 | TETRACYCLIC COMPOUNDS | HTR2C, HTR3D, HTR5A | APP 582/4885HDAC8 3361/4885CYP11B1 4436/4885 |
| US-20130203746-A1 | TETRACYCLIC COMPOUNDS | HTR2C, HTR3D, HTR5A | APP 582/4885HDAC8 3361/4885CYP11B1 4436/4885 |
| US-20130190304-A1 | TETRACYCLIC COMPOUNDS | HTR2C, HTR3D, HTR5A | APP 582/4885HDAC8 3361/4885CYP11B1 4436/4885 |
| US-20090239854-A1 | Tetracyclic compounds | HTR2C, HTR3D, HTR5A | APP 582/4885HDAC8 3361/4885CYP11B1 4436/4885 |
| US-20140194414-A1 | TETRACYCLIC COMPOUNDS | HTR2C, HTR3D, HTR5A | APP 582/4885HDAC8 3361/4885CYP11B1 4436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.